Health ❯ Healthcare ❯ Medical Treatments

Cell Therapy

CAR T-cell Therapy iPS Cells Stem Cell Therapy Zemcelpro UM171 Cell Therapy Autoimmune Disorders

Kyverna CAR-T Delivers Positive Phase 2 Topline in Stiff Person Syndrome as Shares Jump

The company now targets an FDA filing in early 2026 following significant Week 16 mobility gains with no high‑grade toxicities reported.

EU Grants Conditional Approval to Zemcelpro for Adults Needing Transplants Without a Matched Donor

CAR T-Cell Therapy Yields Lasting Remission in Chronic Inflammatory Demyelinating Polyneuropathy